1. Introduction
The last decade has brought forward tremendous effort in offering better therapeutic management strategies to patients with hematologic malignancies. These efforts have taken either translational or clinical approaches and resulted in the rapid development of new approaches that are more tailored to the disease and the patient [ 1 ]. These range from the development of chimeric antigen receptor T-cells (CAR-T cells) to small inhibitory molecules and different varieties of antibodies. Nevertheless, this rapid development of a wide variety of targets is accompanied by a myriad of side-effects, most of which are interdisciplinary and involve clinical scenarios that are challenging both for hematologists and intensive care unit (ICU) physicians. In treating a patient diagnosed with a hematological malignancy, hematologists and oncologists collaborate with other medical specialties to provide a better outcome, and this often includes the departments of cardiology, pneumology or nephrology. Thus, all clinicians have to be up-to-date with the latest progress in immunotherapy and stem cell transplantation. To meet this endeavor, this manuscript offers an overview of the side-effects of novel therapies for all malignancies in order to improve the management of patients under these treatments.
2. Specific Targets in Hematology
Figure 1 shows the typical targets in the main hematological malignancies. Based on this structure, we further present each individual drug for each of these targets and highlight the target-specific side-effects.
Historically, one of the most important targets in malignant hematology is the fusion protein BCR-ABL in chronic myeloid leukemia (CML). The discovery that BCR-ABL can be efficiently targeted has greatly improved the survival of CML patients [ 2 ]. BCR-ABL inhibitors are classified into three generations, and each of the individual drugs present specific side-effects. Imatinib is the first BCR-ABL inhibitor for CML, and it is the first generation of this class of drugs to which other members of the class are frequently compared. Imatinib has a safe side-effect profile, with most patients tolerating it well. Some common side-effects that can appear in this case are represented by nausea, vomiting, muscle and joint pain, headache and diarrhea [ 3 ]. The second generation of BCR-ABL inhibitors is represented by nilotinib, dasatinib and bosutinib. It should be mentioned that there is a certain tendency in Europe to use nilotinib and in the United States to use dasatinib. Each of these three has a characteristic side-effect that is worse and more frequent when compared to imatinib. Nilotinib is more frequently associated with cardiovascular events, whereas dasatinib is associated with pleural effusion and bosutinib with gastrointestinal conditions, especially diarrhea. The third generation is represented by ponatinib, which is also the most potent and can be efficient even for CML patients where resistance develops to first- and second-generation drugs. Nonetheless, the most marked side-effect of this drug is represented by cardiovascular events that are worse and more frequent than in the case of nilotinib [ 4 ].
Generally, drugs that match the patient’s comorbidities with their side-effects should be avoided. Quite frequently, imatinib will be the first choice when treating CML and will be changed to a second-generation BCR-ABL inhibitor if the disease progresses or if the patient presents intolerance to imatinib [ 4 ].
One of the targets for a varied repertoire of drugs, which is expressed on the surface of multiple hematological malignancies, is CD20. For anti-CD20 targets, most side-effects are target-related, as anti-CD20 therapy determines B-cell depletion, with most of these patients requiring immunoglobulin substitution [ 5 ]. Nonetheless, most cases receiving substitution do not report an increase in infections with encapsulated bacteria, showing the efficacy of this countermeasure. Similarly, some therapies target CD19, which presents a similar mechanism of action as in the case of anti-CD20 therapy. These drugs also target B-cells and require immunoglobulin substitution [ 6 ]. Interestingly, when targeting the B-cell maturation antigen (BCMA), no important reduction in immunoglobulins is reported when compared to the case of anti-CD19 or anti-CD20 therapies, even though this antigen is highly expressed on plasma cells. The main side-effects of anti-BCMA therapy are represented by reactions to the drug itself, most commonly infusion-related reactions or allergic reactions, in the case of antibodies, and cytokine release syndrome (CRS) in the case of anti-BCMA CAR-T cells [ 7 ].
Another important target for plasma cells is CD38. Targeting CD38 in multiple myeloma generally has mild side-effects, and the infusion-related reaction is the most prominent. Still, patients receiving the anti-CD38 drug daratumumab require a special transfusion, as further described [ 8 ]. Brentuximab vedotin, an anti-CD30 therapy, is an excellent therapeutic strategy for classic Hodgkin and peripheral T-cell lymphomas, and it is used as a single-agent monotherapy that bridges the transplant for T-cell lymphomas or is used in combination with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy for stage IV Hodgkin lymphomas [ 9 ]. Nonetheless, in addition to the side-effects associated with the monoclonal antibody-based structure of brentuximab vedotin, CD30 is a marker of activated T-cells, thus potentially leading to an impairment of these cells. Peripheral neuropathy is a side-effect that is not life-threatening, but it may lead to the interruption of the treatment or may alter the patient’s quality of life [ 10 ].
One of the targets that significantly impacted treatment of hematological malignancies is BCL2 since its discovery by the team of Croce et al. [ 11 , 12 , 13 , 14 ]. Currently, the most used drug that targets BCL2 is venetoclax. Currently, this drug impacts a variety of hematological malignancies, most notably chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [ 15 , 16 ]. The main side-effect arises from the anti-apoptotic role of BCL2. Because of this, venetoclax is linked to a high tumor lysis syndrome when used without caution. Nonetheless, this side-effect can be avoided in most cases through correct dose escalation, prior cytoreduction and renal protection [ 17 ].
The checkpoint blockade in cancer was awarded the 2018 Nobel prize in Medicine or Physiology [ 18 ]. It acts by releasing some of the regulatory effects that occur either between the T-cell and the antigen-presenting cell (APC) or between the T-cell and the malignant cell. Because T-cells are likely to recognize a more altered antigen repertoire as non-self, checkpoint blockers have a more significant effect in malignancies with a higher degree of genomic instability. Because of this, nivolumab and pembrolizumab were approved for use in any malignancy with genomic instability [ 19 ]. The main side-effect of this class of molecules is caused by their T-cell activation mechanism. Still, although it enhances the action of T-cells against malignant cells, it also increases the probability for T-cells to recognize self-structures as non-self, leading to autoimmune conditions and associated side-effects [ 20 ].
Immunomodulators, represented by thalidomide, lenalidomide and pomalidomide, act by altering the targets in the proteasomal degradation pathway, leading to an increased degradation of Ikaros family zinc family protein 1 (IKZF1) and IKZF3, which in turn reduces myelocytomatosis (MYC) transcription. Moreover, this class of molecules inhibits the overall proteasomal degradation pathway, leading to protein accumulation and thus being important for diseases which produce an increased number of proteins, as in the case of multiple myeloma [ 21 , 22 ]. Apart from the teratogenic effects that thalidomide is known for, the main side-effects that occur in patients treated with these compounds are pancytopenia and neuropathic pain. However, besides these two side-effects, the drugs are generally well tolerated [ 23 , 24 ].
Fms-like tyrosine kinase (FLT3) is an important target especially for FLT3-internal tandem duplication (ITD) AML, as this alteration is associated with a bad prognosis [ 25 ]. The first generation of FLT3 inhibitors is most frequently represented by midostaurin and the second by gilteritinib and quizartinib. The side-effect profile of this class is generally well tolerated with increased probability of developing cytopenias when combined with venetoclax [ 25 , 26 , 27 ].
BTK inhibitors are very efficient for the treatment of CLL and have few side-effects, the downside being a life-long therapy. The side-effect profile is generally well tolerated, so extended use of these drugs does not lead to significant discomfort for most patients. Nonetheless, ibrutinib, the most commonly used BTK inhibitor, causes blood thinning and arrhythmias and must be stopped 3 days before and after a minor surgical intervention, as well as 7 days before and after a major surgical intervention. Considering that CLL develops over a long period of time, these stops are generally not of concern [ 28 ].
PI3K inhibitors have been included in several clinical trials for lymphoid diseases. Nonetheless, an important percentage of them were not validated clinically because of the high degree of side-effects that can occur. The most frequently used compound in this case is idelalisib, which induces severe diarrhea in many patients. Because of this toxicity, clinical trials for this drug were generally conducted as monotherapy, as when used in combined therapy they revealed an unacceptable side-effect profile. Nonetheless, these drugs have been shown to be very active in lymphoid diseases, thus having potential clinical use if the side-effect profile can be better managed [ 29 ]. An important drug that revolutionized symptom management in primary myelofibrosis is ruxolitinib [ 30 , 31 , 32 ]. This drug inhibits both JAK1 and JAK2, thus reducing proinflammatory cytokine levels and, because of this, the size of the spleen and severity constitutional symptoms. The side-effects that occur in this case are related to the role of JAK2 as an important transducer in myeloid differentiation and of JAK1 in other cytokine signaling pathways [ 33 , 34 , 35 ]. The first is responsible for inducing pancytopenia to the point that ruxolitinib has to be reduced or discontinued, and the latter transducer could potentially be responsible for the extreme weight gain that these patients observe under treatment [ 36 , 37 ].
3. CAR-T Cells and Bispecific Antibodies
A novel category of therapies that must be considered is represented by CAR-T cells. These are T-cells that are engineered to present a receptor for a specific antigen that, when encountering the antigen, activate the engineered T-cell. A common effect among this class of therapeutics is cytokine release syndrome (CRS) that occurs between 60% and 80% of treated patients [ 38 , 39 , 40 , 41 ]. CRS is characterized by a massive release of inflammatory cytokines and subsequent multiorgan dysfunction. Additionally, because of these cytokines, neurological and pulmonary symptoms can occur separately from CRS. In addition to these class effects, side-effects can also be in accordance to the target of the CAR-T cell, most notably anti-CD19, also requiring intravenous immunoglobulins [ 42 ].
A similar class of therapeutics considering the mechanism of action is represented by bispecific antibodies. In these cases, one arm of these molecules binds CD3 on T-cells and the other arm binds to the target antigen, generally represented by CD19 on the malignant clone. Of note, these also present CRS, but in a smaller proportion compared to CAR-T cells [ 43 ].
To offer an overview of the side-effects of the therapies that are frequently used, we classified them according to the FDA approval status and on the systems affected ( Figure 2 , Figure 3 , Figure 4 , Figure 5 , Figure 6 , Figure 7 and Figure 8 ), and we offer a summary of their molecular mechanisms that might explain the observed side-effects ( Table 1 ).
4. Conclusions
In the current concise review, we offered an overview of the most common therapies that are used in hematology with the main interest that other specialties would find this of use when collaborating with a hematologist. Nonetheless, this should only serve as a primer for understanding the hematologic patient and should not substitute discussions with a hematologist or further consulting the specific literature.
Author Contributions
All authors contributed to the conceptualization of the manuscript. (C.C.) and (S.P.) wrote the manuscript. (C.T.) and (H.E.) supervised the work. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by from an internal grant of the School of Doctoral Studies-Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca (PCD 2019-2022)(Catalin Constantinescu); as well as by a grant from the Romanian Ministry of Research and Innovation, CCCDI-UEFISCDI, Project No. PN-III-P4-ID-PCCF-2016-0112, acronym NanoTEX, as well as by a grant awarded for Young Research Teams 2020-2022 (Grant No. PN-III-P1-1.1-TE-2019-0271, acronym Seattle), and by an international collaborative grant of the European Economic Space between Romania and Iceland 2020-2022 (Grant No. 19-COP-0031, acronym HERO).
Conflicts of Interest
The authors declare no potential conflict of interest.
References
1. Coller B.S. Blood at 70: Its roots in the history of hematology and its birth Blood 2015 126 2548 2560 10.1182/blood-2015-09-659581 26631112 PMC4671105
2. Goldman J.M. Chronic Myeloid Leukemia: A Historical Perspective Semin. Hematol. 2010 47 302 311 10.1053/j.seminhematol.2010.07.001 20875546
3. Hochhaus A. Baccarani M. Silver R.T. Schiffer C. Apperley J.F. Cervantes F. Clark R.E. Cortes J.E. Deininger M.W. Guilhot F. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia Leukemia 2020 34 966 984 10.1038/s41375-020-0776-2 32127639 PMC7214240
4. Jabbour E. Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring Am. J. Hematol. 2020 10.1002/ajh.25792 32239758
5. Marshall M.J.E. Stopforth R.J. Cragg M.S. Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? Front. Immunol. 2017 8 1245 10.3389/fimmu.2017.01245 29046676 PMC5632755
6. Makatsori M. Kiani-Alikhan S. Manson A.L. Verma N. Leandro M. Gurugama N.P. Longhurst H.J. Grigoriadou S. Buckland M. Kanfer E. Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes QJM 2014 107 821 828 10.1093/qjmed/hcu094 24778295
7. Shah N. Chari A. Scott E. Mezzi K. Usmani S.Z. B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches Leukemia 2020 34 985 1005 10.1038/s41375-020-0734-z 32055000 PMC7214244
8. Morandi F. Horenstein A.L. Costa F. Giuliani N. Pistoia V. Malavasi F. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma Front. Immunol. 2018 9 2722 10.3389/fimmu.2018.02722 30546360 PMC6279879
9. Connors J.M. Jurczak W. Straus D.J. Ansell S.M. Kim W.S. Gallamini A. Younes A. Alekseev S. Illés Á. Picardi M. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma N. Engl. J. Med. 2018 378 878 10.1056/NEJMoa1708984 29224502 PMC5819601
10. Yi J.H. Kim S.J. Kim W.S. Brentuximab vedotin: Clinical updates and practical guidance Blood Res. 2017 52 243 10.5045/br.2017.52.4.243 29333400 PMC5762734
11. Reed J.C. Tsujimoto Y. Alpers J.D. Croce C.M. Nowell P.C. Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation Science 1987 236 1295 1299 10.1126/science.3495884 3495884
12. Negrini M. Silini E. Kozak C. Tsujimoto Y. Croce C.M. Molecular analysis of mbcl-2: Structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma Cell 1987 49 455 463 10.1016/0092-8674(87)90448-X 3032455
13. Tsujimoto Y. Bashir M.M. Givol I. Cossman J. Jaffe E. Croce C.M. DNA rearrangements in human follicular lymphoma can involve the 5’ or the 3’ region of the bcl-2 gene Proc. Natl. Acad. Sci. USA 1987 84 1329 1331 10.1073/pnas.84.5.1329 3547408 PMC304421
14. Taylor C.R. Classification of lymphoma Arch. Pathol. Lab. Med. 1978 102 549 554 309755
15. Pollyea D.A. Stevens B.M. Jones C.L. Winters A. Pei S. Minhajuddin M. D’Alessandro A. Culp-Hill R. Riemondy K.A. Gillen A.E. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia Nat. Med. 2018 24 1859 1866 10.1038/s41591-018-0233-1 30420752 PMC7001730
16. Seymour J.F. Kipps T.J. Eichhorst B. Hillmen P. D’Rozario J. Assouline S. Owen C. Gerecitano J. Robak T. De la Serna J. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia N. Engl. J. Med. 2018 378 1107 1120 10.1056/NEJMoa1713976 29562156
17. Juárez-Salcedo L.M. Desai V. Dalia S. Venetoclax: Evidence to date and clinical potential DIC 2019 8 1 13 10.7573/dic.212574 PMC6788387 31645879
18. Ledford H. Else H. Warren M. Cancer immunologists scoop medicine Nobel prize Nature 2018 562 20 21 10.1038/d41586-018-06751-0 30279600
19. Marcus L. Lemery S.J. Keegan P. Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors Clin. Cancer Res. 2019 25 3753 3758 10.1158/1078-0432.CCR-18-4070 30787022
20. Khan S. Gerber D.E. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review Semin. Cancer Biol. 2020 64 93 101 10.1016/j.semcancer.2019.06.012 31330185 PMC6980444
21. Manasanch E.E. Orlowski R.Z. Proteasome inhibitors in cancer therapy Nat. Rev. Clin. Oncol. 2017 14 417 433 10.1038/nrclinonc.2016.206 28117417 PMC5828026
22. Nencioni A. Grünebach F. Patrone F. Ballestrero A. Brossart P. Proteasome inhibitors: Antitumor effects and beyond Leukemia 2007 21 30 36 10.1038/sj.leu.2404444 17096016
23. Kotla V. Goel S. Nischal S. Heuck C. Vivek K. Das B. Verma A. Mechanism of action of lenalidomide in hematological malignancies J. Hematol. Oncol. 2009 2 36 10.1186/1756-8722-2-36 19674465 PMC2736171
24. Holstein S.A. Suman V.J. McCarthy P.L. Update on the role of lenalidomide in patients with multiple myeloma Ther. Adv. Hematol. 2018 9 175 190 10.1177/2040620718775629 30013765 PMC6041862
25. Daver N. Schlenk R.F. Russell N.H. Levis M.J. Targeting FLT3 mutations in AML: Review of current knowledge and evidence Leukemia 2019 33 299 312 10.1038/s41375-018-0357-9 30651634 PMC6365380
26. Kiyoi H. FLT3 Inhibitors: Recent advances and problems for clinical application Nagoya J. Med. Sci. 2015 77 7 17 25797966 PMC4361503
27. Perl A.E. Daver N.G. Pratz K.W. Maly J. Hong W.-J. Bahceci E. Tong B. Tian T. Dilley K. Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study Blood 2019 134 3910 10.1182/blood-2019-127416
28. Aalipour A. Advani R.H. Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: Focus on ibrutinib Ther. Adv. Hematol. 2014 5 121 133 10.1177/2040620714539906 25360238 PMC4212313
29. Batlevi C.L. Younes A. Revival of PI3K inhibitors in non-Hodgkin’s lymphoma Ann. Oncol. 2017 28 2047 2049 10.1093/annonc/mdx392 28911078
30. Harrison C. Kiladjian J.-J. Al-Ali H.K. Gisslinger H. Waltzman R. Stalbovskaya V. McQuitty M. Hunter D.S. Levy R. Knoops L. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N. Engl. J. Med. 2012 366 787 798 10.1056/NEJMoa1110556 22375970
31. Tomuleasa C. Selicean S. Gafencu G. Petrushev B. Pop L. Berce C. Jurj A. Trifa A. Rosu A.-M. Pasca S. Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis J. Cell. Physiol. 2018 233 422 433 10.1002/jcp.25902 28294327
32. Schieber M. Crispino J.D. Stein B. Myelofibrosis in 2019: Moving beyond JAK2 inhibition Blood Cancer J. 2019 9 74 10.1038/s41408-019-0236-2 31511492 PMC6739355
33. Fuentes-Mattei E. Bayraktar R. Manshouri T. Silva A.M. Ivan C. Gulei D. Fabris L. Soares do Amaral N. Mur P. Perez C. miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2 JCI Insight 2020 5 10.1172/jci.insight.121781 31941838 PMC7030823
34. Selicean S.E. Tomuleasa C. Grewal R. Almeida-Porada G. Berindan-Neagoe I. Mesenchymal stem cells in myeloproliferative disorders—Focus on primary myelofibrosis Leuk. Lymphoma 2019 60 876 885 10.1080/10428194.2018.1516881 30277128
35. Dobrowolski J. Pasca S. Teodorescu P. Selicean C. Rus I. Zdrenghea M. Bojan A. Trifa A. Fetica B. Petrushev B. Persistent Basophilia May Suggest an “Accelerated Phase” in the Evolution of CALR-Positive Primary Myelofibrosis toward Acute Myeloid Leukemia Front. Oncol. 2019 9 872 10.3389/fonc.2019.00872 31555600 PMC6742718
36. Verstovsek S. Mesa R.A. Gotlib J. Levy R.S. Gupta V. DiPersio J.F. Catalano J.V. Deininger M. Miller C. Silver R.T. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis N. Engl. J. Med. 2012 366 799 807 10.1056/NEJMoa1110557 22375971 PMC4822164
37. Harrison C.N. Vannucchi A.M. Kiladjian J.-J. Al-Ali H.K. Gisslinger H. Knoops L. Cervantes F. Jones M.M. Sun K. McQuitty M. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis Leukemia 2016 30 1701 1707 10.1038/leu.2016.148 27211272 PMC5399157
38. Deak D. Pop C. Zimta A.-A. Jurj A. Ghiaur A. Pasca S. Teodorescu P. Dascalescu A. Antohe I. Ionescu B. Let’s Talk about BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia Front. Immunol. 2019 10 2856 10.3389/fimmu.2019.02856 31921126 PMC6934055
39. Constantinescu C. Pasca S. Tat T. Teodorescu P. Vlad C. Iluta S. Dima D. Tomescu D. Scarlatescu E. Tanase A. Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies? J. Immunother. Cancer 2020 8 10.1136/jitc-2020-000742 PMC7264828 32474415
40. Tat T. Li H. Constantinescu C.-S. Onaciu A. Chira S. Osan C. Pasca S. Petrushev B. Moisoiu V. Micu W.-T. Genetically enhanced T lymphocytes and the intensive care unit Oncotarget 2018 9 10.18632/oncotarget.24637 PMC5893262 29662667
41. Tomuleasa C. Fuji S. Berce C. Onaciu A. Chira S. Petrushev B. Micu W.-T. Moisoiu V. Osan C. Constantinescu C. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia Front. Immunol. 2018 9 239 10.3389/fimmu.2018.00239 29515572 PMC5825894
42. Miliotou A.N. Papadopoulou L.C. CAR T-cell Therapy: A New Era in Cancer Immunotherapy CPB 2018 19 5 18 10.2174/1389201019666180418095526 29667553
43. Newman M.J. Benani D.J. A review of blinatumomab, a novel immunotherapy J. Oncol. Pharm. Pract. 2016 22 639 645 10.1177/1078155215618770 26607163
44. Jabbour E. Deininger M. Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia Leukemia 2011 25 201 210 10.1038/leu.2010.215 20861918
45. Kasi P.M. Tawbi H.A. Oddis C.V. Kulkarni H.S. Clinical review: Serious adverse events associated with the use of rituximab—A critical care perspective Crit. Care 2012 16 231 10.1186/cc11304 22967460 PMC3580676
46. Oak E. Bartlett N.L. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma Expert Opin. Drug Saf. 2016 15 875 882 10.1080/14740338.2016.1179277 27139729
47. DiNardo C.D. Pratz K. Pullarkat V. Jonas B.A. Arellano M. Becker P.S. Frankfurt O. Konopleva M. Wei A.H. Kantarjian H.M. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia Blood 2019 133 7 17 10.1182/blood-2018-08-868752 30361262 PMC6318429
48. Bajwa R. Cheema A. Khan T. Amirpour A. Paul A. Chaughtai S. Patel S. Patel T. Bramson J. Gupta V. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study J. Clin. Med. Res. 2019 11 225 236 10.14740/jocmr3750 30937112 PMC6436564
49. Spiers L. Coupe N. Payne M. Toxicities associated with checkpoint inhibitors—An overview Rheumatology 2019 58 vii7 vii16 10.1093/rheumatology/kez418 31816085 PMC6900917
50. Bascones-Martinez A. Mattila R. Gomez-Font R. Meurman J.H. Immunomodulatory drugs: Oral and systemic adverse effects Med. Oral. 2014 e24 e31 10.4317/medoral.19087 PMC3909428 23986016
51. Raza S. Safyan R. Suzanne L. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma CCDT 2017 17 846 857 10.2174/1568009617666170214104426 28201976
52. Cho S.-F. Lin L. Xing L. Li Y. Yu T. Anderson K.C. Tai Y.-T. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma Cancers 2020 12 1473 10.3390/cancers12061473 32516895 PMC7352710
53. Feng D. Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma Scand. J. Immunol. 2020 92 e12910 10.1111/sji.12910 32471019
54. Yang J. Nie J. Ma X. Wei Y. Peng Y. Wei X. Targeting PI3K in cancer: Mechanisms and advances in clinical trials Mol. Cancer 2019 18 26 10.1186/s12943-019-0954-x 30782187 PMC6379961
55. Nunnery S.E. Mayer I.A. Management of toxicity to isoform α-specific PI3K inhibitors Ann. Oncol. 2019 30 x21 x26 10.1093/annonc/mdz440 PMC6923786 31626273
56. Schwartz D.M. Kanno Y. Villarino A. Ward M. Gadina M. O’Shea J.J. Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases Nat. Rev. Drug Discov. 2018 17 78 10.1038/nrd.2017.267 PMC6168198 29282366
57. Sonbol M.B. Firwana B. Zarzour A. Morad M. Rana V. Tiu R.V. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms Ther. Adv. Hematol. 2013 4 15 35 10.1177/2040620712461047 23610611 PMC3629759
58. Furumoto Y. Gadina M. The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders BioDrugs 2013 27 431 438 10.1007/s40259-013-0040-7 23743669 PMC3778139